{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/mi-secondary-prevention/","result":{"data":{"firstChapter":{"id":"6d17bc7f-3ed1-5a79-b4f4-8e9dc752c658","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 2977ccaf-c346-4df5-9554-fac32bebc271 --><h1>MI - secondary prevention: Summary</h1><!-- end field 2977ccaf-c346-4df5-9554-fac32bebc271 -->","htmlStringContent":"<!-- begin item 7a9e7571-dc63-4576-9591-2c8277f138f4 --><!-- begin field f54ff120-069e-46dc-aaa3-90f46816c6c8 --><ul><li>Myocardial infarction (MI) is necrosis of myocardial tissue following occlusion of a coronary artery and subsequent ischaemia. MI is a major manifestation of coronary heart disease (CHD).</li><li>Death rates from CHD have fallen considerably in the UK since the late 1970s. However, CHD remains one of the most common causes of death in the UK, responsible for approximately 66,000 deaths in 2016.</li><li>The British Heart Foundation (BHF) estimates that in 2016, 2.3 million people in the UK were living with a diagnosis of CHD and around 1 million people had survived an MI.</li><li>The commonest cause of MI is an atheromatous plaque rupturing or eroding in a coronary artery; this causes a coronary thrombus to form, which partially or completely obstructs the artery.</li><li>MIs are divided into 2 types, depending on the ECG changes. <ul><li>ST-segment elevation myocardial infarction (STEMI), which is generally caused by complete and persisting blockage of the artery</li><li>Non-ST-segment elevation myocardial infarction (NSTEMI), reflecting partial or intermittent blockage of the artery.</li></ul></li><li>There are a variety of possible complications which can occur following an MI. including heart failure, angina, depression, and sudden death due to another MI or an arrhythmia.</li><li>Secondary prevention aims to prevent complications or reduce impact, and to prevent further cardiovascular events.</li><li>Secondary prevention include cardiac rehabilitation, addressing relevant lifestyle risk-factors, and drug treatment.</li><li>Lifestyle changes that can reduce the risk of having further MI or other cardiovascular events following an MI include:<ul><li>Smoking cessation.</li><li>A healthy diet.</li><li>Aiming to be moderately physically active for at least 150 minutes per week.</li><li>Losing weight if overweight or obese.</li><li>Keeping alcohol consumption within recommended limits.</li></ul></li><li>All people who have had an MI should be given advice about, and offered, a cardiac rehabilitation programme with an exercise component.<ul><li>This should start as soon as possible, and should normally be initiated in hospital before discharge.</li><li>Other healthcare professionals should be aware of what is involved and encourage ongoing participation.</li></ul></li><li>The following drugs should be offered following an MI (provided there are no contraindications) as they have been shown to reduce the risk of further MI and other cardiovascular events.<ul><li>An angiotensin converting enzyme (ACE) inhibitor (or angiotensin-II receptor antagonist).</li><li>Dual antiplatelet therapy.</li><li>A beta-blocker.</li><li>A statin.</li></ul></li><li>Common concerns that may need to be discussed with a person following an MI include: returning to work and normal activities, driving, sexual activity, erectile dysfunction, air travel, stress, anxiety, and competitive sport.</li><li>Routine further assessment post-MI that should normally be arranged by secondary care include the following:<ul><li>An assessment of left ventricular function.</li><li>An assessment of bleeding risk (usually at a first follow-up hospital appointment post-MI).</li><li>A cardiological assessment to consider whether coronary revascularization is appropriate.</li></ul></li></ul><!-- end field f54ff120-069e-46dc-aaa3-90f46816c6c8 --><!-- end item 7a9e7571-dc63-4576-9591-2c8277f138f4 -->","topic":{"id":"10808f6c-5a83-5526-84e2-5998dee92475","topicId":"0b3a22ee-885a-43aa-8d4b-a290dc2afbcc","topicName":"MI - secondary prevention","slug":"mi-secondary-prevention","aliases":[],"chapters":[{"id":"6d17bc7f-3ed1-5a79-b4f4-8e9dc752c658","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"a57b961c-8bba-5c02-8844-b6307b89222c","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"dc552ddd-7106-5f5f-a7d9-4b2d6f80e1fa","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"e9a32a50-5bdc-5fc0-8ecb-152881ffa7ad","slug":"changes","fullItemName":"Changes"},{"id":"d4c6dcc6-12c6-52a1-957d-47a931a225ec","slug":"update","fullItemName":"Update"}]},{"id":"8c06d36f-1d73-5741-981b-5ed3cc16b7c2","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"cd13560d-8bec-5902-9a9e-2ce26eaa9028","slug":"goals","fullItemName":"Goals"},{"id":"b9d35945-0a30-523a-9ded-6a2ea7f5a79a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5c84a4ff-a034-50b3-b1a3-7cfecfb1e65c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"02b0b701-c0f0-542f-b958-8d30a81301fc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f516bbb5-ea19-5f8f-be12-d8f550493156","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cf211bbf-df50-54c9-b204-ef227db8c62f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3ddc8181-0420-5ae4-8326-2d5ef700203a","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"f303e07d-da7d-5073-b00b-f3dd008f2594","slug":"definition","fullItemName":"Definition"},{"id":"45810734-c13c-5bbd-b314-88dcbfd54c57","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5488a58d-1964-5d60-a54e-a420fd0daeff","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b05c9d6f-fae2-5624-bc64-e5456fa46e84","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"2dd1d8e3-398b-5765-b249-43150874e311","slug":"management","fullItemName":"Management","subChapters":[{"id":"6854ca49-f0af-50f1-8fd3-a6bb900b4bc4","slug":"secondary-prevention","fullItemName":"Scenario: Secondary prevention"}]},{"id":"a4fb09c9-df2a-5800-954a-58fe23af6127","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"e43e8d70-7611-5939-94cb-7cc18a3950a6","slug":"ace-inhibitors","fullItemName":"ACE inhibitors"},{"id":"0220c0cb-0802-5bfa-9d8b-f767f73dbea1","slug":"antiplatelet-treatments","fullItemName":"Antiplatelet treatments"},{"id":"a6c13387-db91-5f87-9795-c95a1be0a245","slug":"beta-blockers","fullItemName":"Beta blockers"},{"id":"064bc21b-4d02-5987-9c23-08b1ca8870d1","slug":"statins","fullItemName":"Statins"}]},{"id":"05c20737-02bb-500e-b3e6-0a506d19e727","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"1ae6e3bc-f751-5c4b-a14d-09c72b74424e","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"a3e487f8-13d0-532b-b16f-d448106af2ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"03c8dfe8-3b8b-5c16-ab71-21f98aa13dcd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a1919ef1-18db-59ab-8c6d-7ef4d649f5d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3e57d884-d476-55de-a85c-a5e4e2001343","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e8c5059d-6ccf-58a3-bb80-1a8273c64c14","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bcfd412e-e461-5a99-a38f-a03a01873fa5","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"10808f6c-5a83-5526-84e2-5998dee92475","topicId":"0b3a22ee-885a-43aa-8d4b-a290dc2afbcc","topicName":"MI - secondary prevention","slug":"mi-secondary-prevention","aliases":[],"topicSummary":"Myocardial infarction (MI), colloquially known as a heart attack, is necrosis of myocardial tissue due to ischaemia.","lastRevised":"Last revised in May 2020","nextPlannedReviewBy":"2024-03-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2024-03","nextPlannedReviewByDisplay":"March 2024","specialities":[{"id":"fe645ae3-9536-5dfb-8c84-285b62195550","name":"Cardiovascular","slug":"cardiovascular"}],"chapters":[{"id":"6d17bc7f-3ed1-5a79-b4f4-8e9dc752c658","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"a57b961c-8bba-5c02-8844-b6307b89222c","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"dc552ddd-7106-5f5f-a7d9-4b2d6f80e1fa","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"e9a32a50-5bdc-5fc0-8ecb-152881ffa7ad","slug":"changes","fullItemName":"Changes"},{"id":"d4c6dcc6-12c6-52a1-957d-47a931a225ec","slug":"update","fullItemName":"Update"}]},{"id":"8c06d36f-1d73-5741-981b-5ed3cc16b7c2","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"cd13560d-8bec-5902-9a9e-2ce26eaa9028","slug":"goals","fullItemName":"Goals"},{"id":"b9d35945-0a30-523a-9ded-6a2ea7f5a79a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5c84a4ff-a034-50b3-b1a3-7cfecfb1e65c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"02b0b701-c0f0-542f-b958-8d30a81301fc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f516bbb5-ea19-5f8f-be12-d8f550493156","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cf211bbf-df50-54c9-b204-ef227db8c62f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3ddc8181-0420-5ae4-8326-2d5ef700203a","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"f303e07d-da7d-5073-b00b-f3dd008f2594","slug":"definition","fullItemName":"Definition"},{"id":"45810734-c13c-5bbd-b314-88dcbfd54c57","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5488a58d-1964-5d60-a54e-a420fd0daeff","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b05c9d6f-fae2-5624-bc64-e5456fa46e84","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"2dd1d8e3-398b-5765-b249-43150874e311","slug":"management","fullItemName":"Management","subChapters":[{"id":"6854ca49-f0af-50f1-8fd3-a6bb900b4bc4","slug":"secondary-prevention","fullItemName":"Scenario: Secondary prevention"}]},{"id":"a4fb09c9-df2a-5800-954a-58fe23af6127","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"e43e8d70-7611-5939-94cb-7cc18a3950a6","slug":"ace-inhibitors","fullItemName":"ACE inhibitors"},{"id":"0220c0cb-0802-5bfa-9d8b-f767f73dbea1","slug":"antiplatelet-treatments","fullItemName":"Antiplatelet treatments"},{"id":"a6c13387-db91-5f87-9795-c95a1be0a245","slug":"beta-blockers","fullItemName":"Beta blockers"},{"id":"064bc21b-4d02-5987-9c23-08b1ca8870d1","slug":"statins","fullItemName":"Statins"}]},{"id":"05c20737-02bb-500e-b3e6-0a506d19e727","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"1ae6e3bc-f751-5c4b-a14d-09c72b74424e","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"a3e487f8-13d0-532b-b16f-d448106af2ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"03c8dfe8-3b8b-5c16-ab71-21f98aa13dcd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a1919ef1-18db-59ab-8c6d-7ef4d649f5d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3e57d884-d476-55de-a85c-a5e4e2001343","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e8c5059d-6ccf-58a3-bb80-1a8273c64c14","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bcfd412e-e461-5a99-a38f-a03a01873fa5","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"10808f6c-5a83-5526-84e2-5998dee92475"}},"staticQueryHashes":["3666801979"]}